| Document |
Document Title |
|
WO/2006/061925 |
A preventive/therapeutic composition for free radical diseases, characterized by containing as an active ingredient at least one of a fullerene, a fullerene derivative, and a composite comprising a fullerene or fullerene derivative and a...
|
|
WO/2006/062110 |
A compound represented by the formula (I): [wherein R1 represents C3-9 branched alkyl; R2 represents, e.g., linear or branched, C2-9 alkyl optionally substituted by halogen, etc.; and X represents oxygen, etc.] (provided that the followi...
|
|
WO/2006/059730 |
[PROBLEMS] An increase in body fat is one of main causes of life-style-related diseases such as hypertension, insulin tolerance, and hyperlipemia. A composition for body fat reduction is provided which inhibits body fat from decreasing o...
|
|
WO/2006/053379 |
A nutraceutical composition including one or more extracts of one or more plant components, the one or more extracts providing a combination of phytonutrient materials, the type and amount of which are in excess of a minimum value predet...
|
|
WO/2006/055412 |
A human having an erythropoietin resistant condition is treated by the administration of an iron chelator. The human can have end-stage renal disease, chronic renal disease, cancer or anemia. Administration of the iron chelator can essen...
|
|
WO/2006/048430 |
The invention relates to salts of N-acyl-L-aspartate-β-monoester and/or of N-acyl-L-glutamate-&gammad -monoester of general formula (I), in which: Mn+ represents a metal or an oligoelement characterized by a valence state n greater than...
|
|
WO/2006/046257 |
An anti-venom composition comprising extracts of active components of the plants Erythina Indica., Eugenia Jambolana, Mangifera lndica and Jasminum sambac combined at effective ratios to prepare the composition that is capable of adminis...
|
|
WO/2006/042479 |
Pharmaceutical composition and food comprising edible carboxylic acid and/or its acid salt and optionally coffeine, crude drug and pharmaceutical acceptable carrier are disclosed. The invention also discloses the use and method of the co...
|
|
WO/2006/045050 |
Described herein are methods for protecting cells from ultrasound-mediated cytolysis.
|
|
WO/2006/043671 |
A composition, an Nrf2 activator and a food containing isohumulons or an isomerized hop extract as the active ingredient. These products are useful in treating, preventing or ameliorating diseases or conditions which can be treated, prev...
|
|
WO/2006/038690 |
A functional food and drink having been enhanced with respect to the functions such as antibacterial, antioxidant, antiallergic, and antitumor properties and protection against hepatic function disorder. There is provided a food or drink...
|
|
WO/2006/037224 |
The invention relates to the field of oxidative stress disorder and more specifically to isolated cells from clk-1 +/- animals that do not express CLK1. The invention also relates to methods for treating a subject or a diseased tissue in...
|
|
WO/2006/035142 |
The invention relates to the preparation of compounds comprising at least one phenol function and one amide function derived from amino-2 alkanol-1 having formula (I) and (II), which have antioxidant and antiradical properties and which ...
|
|
WO/2006/035900 |
Disclosed is an emulsified composition containing coenzyme Q10 which is excellent in storage stability and solubility or dispersibility in water. Also disclosed is an emulsified composition containing coenzyme Q10 which is well absorbed ...
|
|
WO/2006/033351 |
A composition that induces thioredoxin expression, being useful in relaxing of influences from oxidation stress, etc., and that is safe. There is provided a composition for use in the fields of food, pharmaceutical, feed, etc., comprisin...
|
|
WO/2006/033412 |
An alleviator for radiation disorders which is safe even when administered to the living body; and a composition containing the alleviator for radiation disorders. The alleviator for radiation disorders contains &agr -D-glucopyranosyl-(1...
|
|
WO/2006/031337 |
The present invention relates to compositions comprising a combination of PKC activators and PKC inhibitors and methods to modulate &agr -secretase activity; improve or enhance cognitive ability; and/or reduce neurodegeneration in indivi...
|
|
WO/2006/030111 |
The invention concerns biodegradable polymer microparticles comprising each successively in sequence from the core outwards: A) a cationic or anionic hydrophilic biodegradable polymer nucleus consisting of a carbohydrate or polyol or pol...
|
|
WO/2006/027705 |
Methods and intermediates for synthesizing triethylenetetramine and salts thereof, as well as novel triethylenetetramine salts and their crystal structure, and triethylenetetramine salts of high purity.
|
|
WO/2006/024174 |
The present invention describes new biological activities of immunomodulating 6-substituted purinyl compounds which make them particularly useful during the treatment of cancer. Collectively, these new biological activities make these pu...
|
|
WO/2006/025286 |
Constitutional function-improving agents such as an immune function-improving agent, an antioxidative function-improving agent, a motility function-improving agent and a liver function-improving agent each containing a &dgr -amino acid, ...
|
|
WO/2006/022187 |
A coenzyme Q10-containing composition which has a high coenzyme Q10 content without using any synthetic emulsifying agent such as a glycerol/fatty acid ester, polyglycerol/fatty acid ester, organic acid monoglyceride, or sucrose/fatty ac...
|
|
WO/2006/019855 |
Therapeutic compositions are provided. The compositions include a single molecule that can display both antioxidant and carbonyl trapping properties. This can effectively reduce inflammation, oxidative stress and carbonyl stress, such as...
|
|
WO/2006/019844 |
Methods and compositions are provided which contains preparations of calcium chelators, bisphosphonates, antibiotics, antimicrobial agents, cytostatic agents, calcium ATPase and pyrophosphatase pump inhibitors, calcium phosphate-crystal ...
|
|
WO/2006/017935 |
The present invention provides for non-invasive treatment of nerve agent poisoning by administering nerve agent neutralizing enzymes to the pulmonary epithelium of a subject, by inhalation, where they accumulate within the lungs. Localiz...
|
|
WO/2006/016582 |
|
|
WO/2006/016595 |
It is intended to provide a lactoferrin complex which has an excellent storage stability in the presence of water owing to improvements in the stability of lactoferrin in the presence of water and gastric juice, its solubility in the int...
|
|
WO/2006/014028 |
It is intended to provide a method of conveniently obtaining a polyphenol-containing extract, which has various physiological effects such as an antioxidative activity, a tyrosinase inhibitory activity, a liver-protecting effect and effe...
|
|
WO/2006/011559 |
It is intended to provide a composition for eliminating active oxygen in vivo which comprises an aqueous solution containing a nanosize precious metal colloid. This composition for eliminating active oxygen in vivo can be orally taken co...
|
|
WO/2006/008833 |
It is intended to provide a tea polyphenol composition which contains highly pure catechins and yet has relieved bitterness and astringency. Namely, a tea polyphenol composition: (A) containing from 85 to 95% by weight of catechins; (B) ...
|
|
WO/2006/007763 |
The invention relates to a composition that could eliminate human body's abnormalities caused by electromagnetic field, and the composition comprises an efficient amount alga. The invention also relates to a paste that could eliminate hu...
|
|
WO/2006/004458 |
The invention relates to biologically active preparations and is used for producing bioactive astaxanthin-containing agents exhibiting a high antioxidant activity. The aim of said invention is to rationally optimise a component compositi...
|
|
WO/2005/123120 |
A non-liquid vaccine composition including one or more antigen component (s); a pharmaceutically acceptable non-liquid adjuvant therefor; and optionally a non-liquid vaccine protection agent.
|
|
WO/2005/116005 |
It is intended to provide a lipase activity inhibitor which shows a high inhibitory activity on pancreatic lipase, regulates the absorption of fat from meals and/or contributes to the regulation or prevention of obesity, a food and a dri...
|
|
WO/2005/105126 |
It is intended to provide a composition containing wild watermelon extract. More specifically speaking, it is intended to provide an active oxygen eliminator containing wild watermelon extract, a method of producing the same and a method...
|
|
WO/2005/103007 |
The invention relates to organic chemistry, in particular to nitrogen-containing heterocyclic compounds from the group of hydrated quinolines, more specifically a crystalline 6-ethoxy-2,2,4-trimethyl-tetrahydroquinoline and to a method f...
|
|
WO/2005/103012 |
Compounds represented by the general formula (I) and having cysteine protease inhibiting activity, salts, solvates, or N-oxides thereof, or prodrugs of them; and preventive and/or therapeutic agents for diseases in which cysteine proteas...
|
|
WO/2005/102321 |
A composition that through safe intake of active ingredients, is useful for reducing a burden on body at alcohol ingestion and for recuperation from fatigue. There is provided a composition for acceleration of alcohol metabolism or recup...
|
|
WO/2005/099738 |
The present invention relates to various therapeutic uses of an aqueous Laminaria cloustoni algal extract. The extract can be obtained by means of a method in which (a) a dry and ground portion of algae is simultaneously treated with hot...
|
|
WO/2005/097151 |
An antioxidant composition containing a lutein ester and a black rice extract. It is preferable that the ratio of the mass of the lutein ester WL to the mass of the black rice extract WP, i.e., WL/WP is 0.2 or more but not more than 5. I...
|
|
WO/2005/096806 |
It is intended to provide a transgenic rice plant enabling the production of rice usable as “an edible vaccine”, i.e., rice which can induce a desired immune response via transmucosal administration such as oral administration. To ac...
|
|
WO/2005/097814 |
This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis. The method comprises administering to a subject...
|
|
WO/2005/095381 |
Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a compound comprising Formula (I): &num &num STR1&num &num wherein M is N or CR4; Q1 and Q2 are each independently selecte...
|
|
WO/2005/094844 |
An adsorbent for oral administration characterized by comprising active carbon spheres having an average particle diameter of from 50 to 200 μm, a specific surface area determined by the BET method of 700 m2/g or more and a bulk density...
|
|
WO/2005/095587 |
A method of efficiently differentiating and inducing ES cells into somatic stem cells characterized by comprising culturing the ES cells in the presence of a liquid culture medium of the primary culture of somatic stem cells or in the pr...
|
|
WO/2005/089426 |
Compositions and methods for treating or preventing sepsis in an animal are disclosed. The method comprises administering an electrolyzed saline solution to the animal. In one embodiment, the electrolyzed saline solution comprises ozone ...
|
|
WO/2005/087224 |
Disclosed herein are a composition for stabilizing Epigallocatechin gallate (EGCG) in water phase comprising 0.1-25.0% by weight of Epigallocatechin gallate, 0.1-5.0% by weight of a cationic polymer, an anionic polymer or a mixture there...
|
|
WO/2005/082860 |
Tetracyclines are useful as calpain inhibitors, particularly inhibitors of calpain I and II, as demonstrated in enzymatic assays as well as at the cellular and animal levels. Tetracyclines may be used in the treatment of a wide range of ...
|
|
WO/2005/079506 |
This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigenspecific immune response in a mammal. The method is particular...
|
|
WO/2005/074909 |
A drug which contains a combination of the active ingredients comprising at least one remedy for hyperlipemia selected from the group consisting of fibrate compounds (phenofibrate, bezafibrate, salts thereof, etc.) and HMG-CoA reductase ...
|
